Abstract:Hexavalent chromium (Cr(VI)) has been identified as a Class I human carcinogen, but its carcinogenic mechanism is currently unclear. There is still a lack of understanding of its associations with early pulmonary inflammatory damages. Inflammation is an important stage before the occurrence of tumors, and under the long-term stimulation of inflammation, it can promote the development of tumors. In this study, the aim is to explore the effect of Cr(VI) exposure on pulmonary inflammation and its relationship with the mechanism of inflammation cancer transformation. We established a Cr(VI) exposure model in SD rats using tracheal instillation of potassium dichromate solution, and collected samples at the time of cessation of exposure and 14 days after cessation of exposure. Analyzing the experimental results, it was found that the lung index increased after exposure to Cr(VI), promoting the occurrence of apoptosis in lung tissue cells and exacerbating lung tissue damage. The damage situation improved after exposure termination; Inductively coupled plasma mass (ICPRQ) spectrometer detection found that the exposed group had significantly increased levels of blood chromium, blood manganese, blood copper, blood arsenic, urine chromium, urine copper, and urine lead; After two weeks of repair, blood chromium and blood manganese levels were significantly lower than those in the same dose group of the exposure group, while blood copper levels were significantly higher than those in the same dose group of the exposure group. There was no significant difference in blood arsenic levels between the exposure group and the exposure group. Urine chromium and urine lead levels were significantly lower than those in the same dose group of the exposure group, while urine copper levels only increased. At the same time, it was found that Cr(VI) exposure caused disruption of oxidative stress levels in rat lung tissues. After 14-day exposure, Cr(VI) significantly decreased and oxidative stress levels significantly decreased. Further investigation revealed that Cr(VI) induces activation of inflammasomes NLRP3, AIM2, and their signaling pathways in lung inflammatory injuries, but this condition persists even after cessation of exposure. The study suggested that in hexavalent chromium induced lung tissue injuries in rats, NLRP3 and AIM2 inflammasomes and their signaling pathways activation. Furthermore, the characteristic of sustained activation after cessation of exposure was also indicated. These results provide new ideas and references for further elucidating the mechanisms of Cr(VI), lung inflammation and inflammation cancer transformation.

Hexavalent Chromium Cr(VI) Up-Regulates COX-2 Expression Through an NFκB/c-Jun/AP-1–Dependent Pathway

Hexavalent chromium exposure induces lung injury via activation of NLRP3 and AIM2 inflammasomes in rats

Dysregulation of MiR-199a/IL8 pathway in chronic Cr (VI)-induced tumor growth and angiogenesis

The Regulatory Role of COX-2 in the Interaction Between Cr(VI)-induced Endoplasmic Reticulum Stress and Autophagy in DF-1 Cells.

Epigenetic alterations of CXCL5 in Cr(VI)-induced carcinogenesis

Hexavalent Chromium-Induced Alteration of Proteomic Landscape in Human Skin Fibroblast Cells.

Signaling Pathways and Genes Associated with Hexavalent Chromium-Induced Hepatotoxicity

Cr(VI) induces cytotoxicity in vitro through activation of ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction via the PI3K/Akt signaling pathway

Molecular Mechanisms Of Chromium-Induced Carcinogenesis

On the mechanism of Cr (VI)‐induced carcinogenesis: Dose dependence of uptake and cellular responses

Hexavalent chromium promotes differential binding of CTCF to its cognate sites in Euchromatin

Hexavalent chromium induced metabolic reprogramming, carcinogenesis and tumor progression through PDK1 upregulation

Redox sensitive miR-27a/b/Nrf2 signaling in Cr(VI)-induced carcinogenesis

Hexavalent Chromium (cr(vi)) Down-Regulates Acetylation of Histone H4 at Lysine 16 Through Induction of Stressor Protein Nupr1.

Constitutive Activation of Epidermal Growth Factor Receptor Promotes Tumorigenesis of Cr(VI)-transformed Cells through Decreased Reactive Oxygen Species and Apoptosis Resistance Development

Epigenetic and epitranscriptomic mechanisms of chromium carcinogenesis

Reactive Oxygen Species Mediate Cr(VI)-induced Carcinogenesis Through PI3K/AKT-dependent Activation of GSK-3β/β-catenin Signaling.

Gene Expression Profiling and Bioinformatics Analysis in 16HBE Cells Treated by Chromium (VI).

Hexavalent chromium induces mitochondrial dynamics disorder in rat liver by inhibiting AMPK/PGC-1α signaling pathway

Chronic exposure to hexavalent chromium induces esophageal tumorigenesis via activating the Notch signaling pathway

The Role of Epigenetics in the Toxic Effects Induced by Hexavalent Chromium